Table 1. Patients' main characteristics.
| Patient | Age | Stadiation at diagnosis | PCI | Histological type | Grade | Treatment | NACT | Number of cycles | Clinical response | Time from NACT to HIPEC (days) | Previous chemotherapies | Number of cycles |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
65 |
IV |
5 |
Mucinous |
3 |
Upfront |
CBDCA+PTX |
6 |
>50% |
40 |
No |
|
| 2 |
69 |
IV |
0 |
Serous |
2 |
Upfront |
CBDCA+PTX |
6 |
1 |
60 |
No |
|
| 3 |
72 |
IIIc |
4 |
Serous |
3 |
Upfront |
CBDCA+PTX |
4 |
>50% |
36 |
No |
|
| 4 |
42 |
IIIc |
2 |
Serous |
3 |
Upfront |
CBDCA+PTX |
4 |
>50% |
28 |
No |
|
| 5 |
59 |
IIIc |
7 |
Undifferentiated |
3 |
Upfront |
CBDCA+PTX |
3 |
>50% |
30 |
No |
|
| 6 |
64 |
IIIc |
3 |
Undifferentiated |
3 |
Upfront |
CBDCA+PTX |
6 |
>50% |
48 |
No |
|
| 7 |
64 |
IIIc |
3 |
Serous |
3 |
Upfront |
CBDCA+PTX |
4 |
1 |
34 |
No |
|
| 8 |
52 |
IV |
4 |
Serous |
3 |
Relapse |
No |
|
|
|
CBDCA+PTX |
6 |
| 9 |
51 |
IIIc |
4 |
Endometrioid |
3 |
Relapse |
No |
|
|
|
CBDCA+PTX |
5 |
| 10 |
45 |
IIIc |
4 |
Serous |
3 |
Relapse |
No |
|
|
|
CBDCA+PTX; caelyx+yondelis |
6+10 |
| 11 |
48 |
IIIc |
4 |
Serous |
3 |
Relapse |
No |
|
|
|
CBDCA+PTX |
6 |
| 12 |
63 |
IIIc |
5 |
Serous |
3 |
Upfront |
CBDCA+PTX |
3 |
1 |
40 |
|
|
| 13 | 51 | IIIc | 4 | Serous | 3 | Upfront | CBDCA+PTX | 3 | 1 | 36 |
Abbreviations: CBDCA=carboplatin; HIPEC=hyperthermic intraperitoneal chemotherapy; NACT=neoadjuvant chemotherapy; PCI=peritoneal cancer index; PTX=paclitaxel.